The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

January 30, 2020

Thomas J. Scharschmidt, MD, MBOE, discusses the use of targeted muscle reinnervation for amputee patients with cancer as well as therapeutic advances in sarcoma and tenosynovial giant cell tumor.

January 29, 2020

Jeffrey M. Fowler, MD, discusses selection criteria that can help determine which surgical procedure to pursue in ovarian cancer.

January 25, 2020

Ritu Salani, MD, discusses selecting patients with ovarian cancer for primary debulking surgery versus neoadjuvant chemotherapy.

January 24, 2020

Casey M. Cosgrove, MD, discusses the approval of niraparib in advanced ovarian cancer.

January 24, 2020

Jonathan E. Brammer, MD, discusses the progression of transplant in acute lymphoblastic leukemia.

January 23, 2020

Narendranath Epperla, MD, MS, reflects on recent advances in Hodgkin lymphoma and non-Hodgkin lymphoma.

January 23, 2020

Floor J. Backes, MD, discusses toxicity considerations with PARP inhibitors in ovarian cancer.

January 22, 2020

Alice S. Mims, MD, discusses the emergence of targeted therapy in acute myeloid leukemia treatment.

January 18, 2020

Larry J. Copeland, MD, discusses the role of chemotherapy in ovarian cancer.

January 16, 2020

Maria Chaudhry, MBBS, a hematologist at The Ohio State University Comprehensive Cancer Center—James, discusses novel treatment regimens in relapsed/refractory multiple myeloma.

January 15, 2020

John Hays, MD, PhD, discusses the progression of immunotherapy in treating patients with ovarian cancer.

January 15, 2020

Alice S. Mims, MD, discusses developed resistance in acute myeloid leukemia.

January 14, 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

January 11, 2020

Experts from The Ohio State University Comprehensive Cancer Center–James highlighted exciting research being conducted at their institution.

January 10, 2020

Floor J. Backes, MD, discusses the consideration of financial toxicity when choosing a PARP inhibitor for a patient with ovarian cancer.

January 10, 2020

Jonathan E. Brammer, MD, discusses the importance of achieving minimal residual disease negativity in relapsed/refractory acute lymphoblastic leukemia.

January 09, 2020

Alice Mims, MD, discusses biomarker research and therapeutic developments in acute myeloid leukemia.

January 09, 2020

Floor J. Backes, MD, discusses the phase III FILM trial in endometrial cancer.

January 09, 2020

Jonathan E. Brammer, MD, discusses the role of minimal residual disease and transplant in acute lymphoblastic leukemia, as well as the introduction of CAR T-cell therapy and other novel agents to the armamentarium.

January 09, 2020

Alice S. Mims, MD, discusses up front molecular profiling in patients with newly diagnosed acute myeloid leukemia.